HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Claims Emerge To Join “Natural” As Class Action Fodder

This article was originally published in The Tan Sheet

Executive Summary

Claims a product is “natural,” health and prevention claims, “whole grain” and “made with” claims, all can put a firm at risk for a lawsuit, the Center for Science in the Public Interest warns. After climbing for five years in a row, class action lawsuits brought against food products dipped in 2013, but the decline may be short-lived.

You may also be interested in...



Regulatory News In Brief

FTC/Garden of Life case continues; FDA deems ForMor in violation of GMPs; Kanebo faulted for pharmaceutical GMP failures; CytoSport settles litigation over Muscle Milk labeling; USPlabs’ carb claim canned in NAD review; FDA extends comment time on FSMA tracking pilots.

J&J Settles Class Action For “Misleading” Neutrogena Naturals Claims

The case hinges on claims used to promote Neutrogena Naturals cleansers and moisturizers – specifically, that they are “natural products that contain no petrochemicals,” according to court documents. The consumer plaintiffs say they paid a premium over “comparable products” on the basis of those claims.

In Absence Of Standards For Natural, NAD Focuses On Context

Without regulatory guidelines, the National Advertising Division evaluates natural claims based on consumer expectations and the context in which they are used, a staff attorney says. Speakers at NAD’s annual meeting said natural claims guidance is not an FDA priority, but industry might be better off without regulatory input.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS123991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel